EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieOpen Access

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer

Makoto Tahara iD, Naomi Kiyota iD, Takeshi Kodaira iD, Hiroshi Nishino iD, Yukinori Asada, Hiroki Mitani, Yuji Hirayama, Yusuke Onozawa, Naoki Nishio iD, Nobuhiro Hanai iD, Akira Ohkoshi iD, Hiroki Hara iD und 21 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-01708 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Makoto Tahara und 32 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Chemoradiotherapy, Cisplatin, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m 2 once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m 2 once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin. A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsChemoradiotherapyCisplatinHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedDrug Administration ScheduleFollow-Up Studies

Substanzen

Antineoplastic AgentsCisplatin

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Kobe University Hospital, Cancer Center, Kobe, Japan.
  • Aichi Cancer Center Hospital, Nagoya, Japan.
  • Jichi Medical University Hospital, Shimotsuke, Japan.
  • Miyagi Cancer Center, Natori, Japan.
  • Cancer Institute Hospital, Tokyo, Japan.

ORCID-Profile: Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Naoki Nishio, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Masato Nagaoka, Shujiro Minami, Kaoru Tanaka, Seiichi Yoshimoto, Tsutomu Ueda, Yo Kishimoto, Akihiro Homma, Nobuhiko Oridate, Hirokazu Uemura, Katsunori Katagiri, Tomoko Yamazaki, Shigeyuki Murono, Junki Mizusawa, Kenichi Nakamura

Zitieren

APA

Tahara, M., Kiyota, N., Kodaira, T., Nishino, H., Asada, Y., Mitani, H., Hirayama, Y., Onozawa, Y., Nishio, N., Hanai, N., Ohkoshi, A., Hara, H., Monden, N., Nagaoka, M., Minami, S., Tanaka, K., Fujii, T., Yoshimoto, S., Ueda, T., …, & Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG) (2026). Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01708

Vancouver

Tahara M, Kiyota N, Kodaira T, Nishino H, Asada Y, Mitani H, et al. Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-01708

BibTeX
@article{Tahara2026,
  author = {Tahara, Makoto and Kiyota, Naomi and Kodaira, Takeshi and Nishino, Hiroshi and Asada, Yukinori and Mitani, Hiroki and Hirayama, Yuji and Onozawa, Yusuke and Nishio, Naoki and Hanai, Nobuhiro and Ohkoshi, Akira and Hara, Hiroki and Monden, Nobuya and Nagaoka, Masato and Minami, Shujiro and Tanaka, Kaoru and Fujii, Takashi and Yoshimoto, Seiichi and Ueda, Tsutomu and Kishimoto, Yo and Homma, Akihiro and Oridate, Nobuhiko and Okami, Kenji and Uemura, Hirokazu and Katagiri, Katsunori and Yamazaki, Tomoko and Asakage, Takahiro and Saito, Yuki and Murono, Shigeyuki and Mizusawa, Junki and Nakamura, Kenichi and Hayashi, Ryuichi and Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG), Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG)},
  title = {Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-01708}
}
Kostenlos starten →